A retrospective study of tocilizumab to evaluate the effects body mass index on response, in patients with rheumatoid arthritis in real life.
Phase of Trial: Phase IV
Latest Information Update: 27 Jul 2015
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 27 Jul 2015 New trial record
- 13 Jun 2015 The Primary endpoint (Decrease in DAS28 ≥1.2 ) was not met as per results presented at the 16th Annual Congress of the European League Against Rheumatism
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.